Skip to main content


21.08.2019 Client news

NY Attorney General recognizes MedImpact for assisting in multimillion dollar medicaid FWA investigation.

Fraud, waste, and abuse (FWA) is a national crisis that costs our healthcare system at least $200 billion every year. Even worse, research suggests that only a mere 5% of these losses are recovered.1

One of the fastest growing areas of FWA involves pharmacies and prescription drug billing — with federal investigators seeing caseloads quadruple over the past five years.2 But as the fight against FWA intensifies, perpetrator schemes grow more and more sophisticated.

Last month, a New York City pharmacist was arrested, along with three of her pharmacy managers, for their alleged roles in a multimillion dollar Medicaid scheme involving HIV drugs and kickbacks, defrauding Medicaid out of more than $10 million.

According to recent charges filed by the NY Attorney General, the defendants allegedly paid or directed employees to pay cash kickbacks to Medicaid recipients in return for each patient’s agreement to fill their HIV prescriptions. The pharmacy then allegedly billed and received hundreds of thousands of dollars from Medicaid for refills that were not dispensed to patients through auto-refilling schemes.

In conjunction with the criminal case, the Attorney General filed civil actions to recover more than $22 million dollars in damages from the defendants for allegedly defrauding New York’s Medicaid program. Hundreds of bottles of adulterated, diverted HIV medication were also found during the investigation.

MedImpact — along with the New York State Department of Health, the U.S. Department of Health and Human Services, and several other healthcare organizations — were recognized for their assistance throughout the fraud investigation in a press release issued by the NY Attorney General.


1 The Economist:
2 U.S. Department of Justice:


Read on.
Keep up to date on the latest in the industry.
Client news
Dispelling the myth: generics are not always low cost.
When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know:
Client news
FDA approves first and only treatment for common mutation in advanced breast cancer.
The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.
Client news
Can you put a price on life?
FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.

Ready for clarity from your PBM?